Surgery after PARP inhibitor failure in returning ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and your cancer is epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Your cancer is on its first return, after being “platinum sensitive,” and it stayed away for at least 6 months after platinum chemotherapy
- Your cancer progressed while you were on PARP inhibitor maintenance
- Scans suggest the tumor can be completely removed with surgery (no spread in the abdomen that can’t be reached, based on CT/MRI)
- You must not have more than one prior chemotherapy, and this must be the first recurrence (not second or later)
- You should be healthy enough for surgery and chemo, and not on medicines that significantly raise surgical bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
This trial tests if a second surgery followed by heated chemotherapy delivered directly into the abdomen can help people with ovarian, fallopian tube, or peritoneal cancer whose disease has returned while on a PARP inhibitor.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.